Introduction {#s1}
============

Asthma is one of the most common chronic respiratory diseases, characterized by wheezing, cough, and bronchial hyperresponsiveness. It is believed to be a multifactorial disorder with a strong genetic component [@pone.0056065-Umetsu1], [@pone.0056065-vonMutius1]. Interleukin-13 (IL-13) is a central effector cytokine of allergic inflammation. Huang et al. [@pone.0056065-Huang1] found that a significant enhancement of both IL-13 transcripts and secreted proteins in the allergen-challenged bronchoalveolar lavage (BAL) compared with the saline-challenged control sites of asthmatic and rhinitic patients. Furthermore, in human subjects with asthma, the IL-13 concentration in peripheral blood was increased across disease severity in a stable state and was up-regulated at exacerbations [@pone.0056065-Lee1], [@pone.0056065-Wong1]. Recently, Corren et al. [@pone.0056065-Corren1] reported that lebrikizumab treatment in 219 adults who had inadequately controlled asthma was associated with improved lung function. These results strongly suggested that IL-13 had an important role in the pathogenesis of asthma and the *IL-13* gene may be a susceptibility gene of asthma.

So far, a lot of studies investigated the association between the *IL-13* gene polymorphisms and susceptibility of asthma [@pone.0056065-vanderPouwKraan1]--[@pone.0056065-Munoz1]. Most of them focused on two polymorphisms: -1112C/T and +2044A/G. However, the results from these studies were inconsistent. Although two meta-analyses on these polymorphisms have be published [@pone.0056065-Yang3], [@pone.0056065-Cui1], some inconsistent results still existed. For example, Yang et al. [@pone.0056065-Yang3] reported that *IL-13*+2044A allele was associated with an increased risk of asthma among Asians but not among Caucasians. However, Cui et al. [@pone.0056065-Cui1] found that *IL-13*+2044A/G polymorphism was associated Caucasians but not Asians. In addition, these two meta-analyses did not evaluate the association between *IL-13* polymorphisms and atopic asthma. Hence, we performed a meta-analysis of all eligible studies to derive more precise estimation of the associations of *IL-13* −1112C/T and +2044A/G polymorphisms with asthma risks. This was, to our knowledge, the most comprehensive meta-analysis of the association between *IL-13* polymorphisms and asthma susceptibility.

Methods {#s2}
=======

Publication Search {#s2a}
------------------

Published studies were identified through a computerized search of Pubmed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Wangfang databases (Last search was updated on October, 2012). The search terms were used as follows: (asthma or asthmatic) and (interleukin-13 or IL-13) and (polymorphism or mutation or variant). We also perused the reference lists of all retrieved articles and relevant reviews. There was no language restriction.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Studies included in the current meta-analysis should meet the following criteria: (1) evaluation of the polymorphisms in *IL-13* gene and asthma risk, (2) using a case-control design, (3) genotype distributions in both cases and controls should be available for estimating an odds ratio (OR) with 95% confidence interval (CI).

Studies were excluded if one of the following existed: (1) not relevant to *IL-13* or asthma risk, (2) not designed as case-control studies, (3) genotype frequencies or number not offered, (4) non-clinical studies, (5) editorials, reviews and abstracts, and (6) not consistent with Hardy-Weinberg equilibrium (HWE). In the case of overlapping studies, only the one with the largest sample numbers was included.

Data Extraction {#s2c}
---------------

Data were extracted from all eligible studies independently by two of the authors (Nie and Liu). The relevant data were extracted into predesigned data collection forms. The following information was collected from each study: first author's name, year of publication, original country, ethnicity, age group, atopic status, sample size, genotyping method, and genotype number in cases and controls. We verified accuracy of data by comparing collection forms from each investigator. If a decision could not be made regarding inclusion, the full text of the article was examined.

Qualitative Assessment {#s2d}
----------------------

Two authors (Nie and Liu) assessed the quality of each study independently. The quality scoring system was based on traditional epidemiologic considerations and asthma genetic issues [@pone.0056065-Thakkinstian1]. Scores ranged from the lowest zero to the highest fifteen. Studies with quality scores ≤4 were defined as low quality studies [@pone.0056065-Li2].

Statistical Analysis {#s2e}
--------------------

When the data from at least 3 similar studies were available, meta-analysis was performed. The strength of the association between the *IL-13* polymorphisms and asthma risk was measured by ORs and 95% CIs. The statistical significance of summary OR was determined with *Z* test. OR1, OR2, and OR3 were calculated for the genotypes: 1). TT vs. CC (OR1), TC vs. CC (OR2), and TT vs. TC (OR3) for the -1112C/T polymorphism, 2). AA vs. GG (OR1), AG vs. GG (OR2), and AA vs. AG (OR3) for the +2044A/G polymorphism. These pairwise differences were used to indicate the most appropriate genetic model [@pone.0056065-Thakkinstian2]--[@pone.0056065-Nie2]. Once the best genetic model was identified, this model was used to collapse the three genotypes into two groups (except in the case of a codominant model) and to pool the results. We used a random-effects model to calculate the pooled ORs.

Heterogeneity among studies was examined with *I^2^* statistic. *I^2^* takes a value of 0--100% (*I^2^* = 0--25%, no heterogeneity; *I^2^* = 25--50%, moderate heterogeneity; *I^2^* = 50--75%, large heterogeneity; *I^2^* = 75--100%, extreme heterogeneity). A chi-square based Q-test was also performed to check the betweenstudy heterogeneity, which was considered to be significant for *P\<*0.10. To explore the source of the heterogeneity and evaluate the ethnic-specific, atopic-specific effects, subgroup analyses were performed by ethnicity and atopic status. To access the stability of the meta-analysis, one-way sensitivity analyses were carried out. We did cumulative meta-analysis by undertaking sequential random-effects pooling, starting with the earliest studies. Results were presented as a series of mini meta-analyses, which were ordered chronologically in a forest plot to show the consequence of adding studies on the effect size. Departure from HWE in controls was tested by the chi-square test. Publication bias was assessed by visual inspection of funnel plots, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was assessed by Egger's linear regression test [@pone.0056065-Egger1].

All statistical tests were performed by using the Revman 5.1 software (Nordic Cochrane Center, Copenhagen, Denmark) and STATA 11.0 software (Stata Corporation, College Station, TX). A *P* value \<0.05 was considered statistically significant.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

The flow chart in [**Figure 1**](#pone-0056065-g001){ref-type="fig"} summarizes this literature review process. In this current study, a total of 34 eligible studies met the inclusion criteria [@pone.0056065-vanderPouwKraan1]--[@pone.0056065-Munoz1]. Four articles reported two cohorts [@pone.0056065-Xi1], [@pone.0056065-Donfack1], [@pone.0056065-Undarmaa1], [@pone.0056065-Baye1], and each cohort was considered as a case-control study. There were 22 studies on -1112C/T polymorphism and 31 studies on +2044A/G polymorphism. There were 18 studies performed using Asians, 13 studies using Caucasians, and 4 studies using African Americans. Ten studies were performed in adults and seventeen in children. Seven studies included only atopic asthma patients, six studies included both of atopic and non-atopic asthma patients but data for these patients could be separately extracted, and 19 studies did not report detailed information. Quality scores for the individual studies ranged from 5 to 12. The characteristics of each study included in this meta-analysis are presented in [**Table 1**](#pone-0056065-t001){ref-type="table"}. Genotype frequencies and HWE examination results are listed in [**Table 2**](#pone-0056065-t002){ref-type="table"}.

![Flow of study identification, inclusion, and exclusion.](pone.0056065.g001){#pone-0056065-g001}

10.1371/journal.pone.0056065.t001

###### Characteristics of the case-control studies included in meta-analysis.

![](pone.0056065.t001){#pone-0056065-t001-1}

  First authors/references                               Year     Country        Ethnicity       Age group               Atopic status                Case(n)   Control(n)         Genotypingmethod          Qualityscore
  ----------------------------------------------------- ------ ------------- ------------------ ----------- ---------------------------------------- --------- ------------ ------------------------------- --------------
  van der Pouw Kraan [@pone.0056065-vanderPouwKraan1]    1999   Netherlands      Caucasian          NA                       Atopic                     101        107                  PCR-OLA                   5
  Hakonarson [@pone.0056065-Hkonarson1]                  2001     Iceland        Caucasian         Mixed                     Atopic                     94          94                    PCR                     10
  Howard [@pone.0056065-Howard1]                         2001     Holland        Caucasian        Adults     Mixed[\*](#nt101){ref-type="table-fn"}     171        119                Sequencing                  9
  Kauppi [@pone.0056065-Kauppi1]                         2001     Finland        Caucasian          NA                         NA                       163        132                    PCR                     7
  Leung [@pone.0056065-Leung1]                           2001      China           Asian         Children    Mixed[\*](#nt101){ref-type="table-fn"}     157         54                 PCR-RFLP                   9
  Xi 1 [@pone.0056065-Xi1]                               2004      China           Asian          Adults                       NA                       45          46                 PCR-RFLP                   5
  Xi 2 [@pone.0056065-Xi1]                               2004      China           Asian         Children                      NA                       43          31                 PCR-RFLP                   5
  Wu [@pone.0056065-Wu1]                                 2004      China           Asian           Mixed                       NA                       100        100                 PCR-RFLP                   7
  Donfack 1 [@pone.0056065-Donfack1]                     2005       USA          Caucasian          NA       Mixed[\*](#nt101){ref-type="table-fn"}     126        205               DNAprint, LAS                9
  Donfack 2 [@pone.0056065-Donfack1]                     2005       USA       African American      NA       Mixed[\*](#nt101){ref-type="table-fn"}     205        183               DNAprint, LAS                9
  Moissidis [@pone.0056065-Moissidis1]                   2005       USA       African American     Mixed                       NA                       61         157                 PCR-RFLP                   5
  Zhao [@pone.0056065-Zhao1]                             2005      China           Asian         Children                      NA                       130        100                 PCR-RFLP                   7
  Kabesch [@pone.0056065-Kabesch1]                       2006     Germany        Caucasian       Children                      NA                       73         773                 PCR-RFLP                   9
  Battle [@pone.0056065-Battle1]                         2007       USA       African American     Mixed                       NA                       264        176                 PCR-RFLP                   11
  Kang [@pone.0056065-Kang1]                             2007      Korea           Asian         Children                      NA                       374        242                 PCR-RFLP                   11
  Chan [@pone.0056065-Chan1]                             2008      China           Asian         Children                    Mixed                      273        141                 PCR-RFLP                   7
  Kim [@pone.0056065-Kim1]                               2008      Korea           Asian         Children    Mixed[\*](#nt101){ref-type="table-fn"}     715        240                 PCR-RFLP                   10
  Black [@pone.0056065-Black1]                           2009       UK           Caucasian        Adults                       NA                       275        2453            Tetra primer PCR               11
  Daley [@pone.0056065-Daley1]                           2009    Australia       Caucasian         Mixed                       NA                       644        751                 Illumina                   9
                                                                                                                                                                                      Bead Array            
                                                                                                                                                                                        System              
  H Li [@pone.0056065-Li1]                               2009      China           Asian         Children                      NA                       192        192                 PCR-RFLP                   8
  Jiang [@pone.0056065-Jiang1]                           2009      China           Asian           Mixed                       NA                       24          24                 PCR-RFLP                   7
  Llanes [@pone.0056065-Llanes1]                         2009      Spain         Caucasian        Adults                     Atopic                     109         50                 PCR-RFLP                   8
  Wang [@pone.0056065-Wang1]                             2009      China           Asian         Children                    Mixed                      446        511                  Taqman                    8
  Feng [@pone.0056065-Feng1]                             2009      China           Asian         Children                      NA                       45          43                    PCR                     6
  Wang [@pone.0056065-Wang2]                             2009      China           Asian          Adults                       NA                       150        160                 PCR-RFLP                   6
  Bottema [@pone.0056065-Bottema1]                       2010   Netherlands      Caucasian        Adults                     Atopic                     115         92                 MassARRAY                  8
  Dmitrieva-Zdorova [@pone.0056065-DmitrievaZdorova1]    2010     Russia         Caucasian        Adults                     Atopic                     283        227        MALDI-TOF mass-spectrometry         5
  Palikhe [@pone.0056065-Palikhe1]                       2010      Korea           Asian          Adults                       NA                       463        430                 SNAPshot                   6
  Undarmaa 1 [@pone.0056065-Undarmaa1]                   2010      Japan           Asian         Children                    Atopic                     325        336                TaqMan-ASA                  9
  Undarmaa 2 [@pone.0056065-Undarmaa1]                   2010      Japan           Asian          Adults                     Atopic                     367        676                TaqMan-ASA                  9
  Wu XH [@pone.0056065-Wu2]                              2010      China           Asian         Children                      NA                       252        227                 PCR-RFLP                   8
  Yang LF [@pone.0056065-Yang1]                          2010      China           Asian         Children                      NA                       178        158                 PCR-RFLP                   5
  DeWan [@pone.0056065-DeWan1]                           2010       USA            Mixed         Children                    Atopic                     104        503                Affymetrix                  11
                                                                                                                                                                                   Genome-Wide Human        
                                                                                                                                                                                 SNP Array 5.0, TaqMan      
  Yang XX [@pone.0056065-Yang2]                          2011      China           Asian          Adults     Mixed[\*](#nt101){ref-type="table-fn"}     193        204        MALDI-TOF mass-spectrometry         7
  Baye 1 [@pone.0056065-Baye1]                           2011       USA          Caucasian       Children                      NA                       413        298                   IGGAS                    9
  Baye 2 [@pone.0056065-Baye1]                           2011       USA       African American   Children                      NA                       315         51                   IGGAS                    9
  Noguchi [@pone.0056065-Noguchi1]                       2011      Japan           Asian         Children                    Mixed                      938        2376         Illumina HumanHap550v3            12
                                                                                                                                                                             /610-Quad Genotyping BeadChip  
  Munoz [@pone.0056065-Munoz1]                           2012     Mexico         Caucasian       Children                      NA                       90         111                  TaqMan                    5

Data for atopic or non-atopic asthma patients could be separately extracted.

PCR, polymerase chain reaction; OLA, oligonucleotide ligase assay; RFLP, restriction fragment length polymorphism; LAS, multiplex PCR and an immobilized linear array system; TaqMan-ASA, TaqMan allele-specific amplification method; IGGAS, Illumina GoldenGate Assay system; NA, not available.

10.1371/journal.pone.0056065.t002

###### Distribution of *IL-13* genotype among patients and controls.
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  Studies                     Asthma   Control   HWE                 
  -------------------- ----- -------- --------- ------ ------ ------ -------
  −1112C/T                                                           
  van der Pouw Kraan    57      31       13       77     28     2     0.765
  Howard                99      63        9       87     30     2     0.748
  Wu                    50      37       13       69     25     6     0.087
  Donfack 1             72      42       12      126     71     8     0.607
  Donfack 2             69     100       36       66     85     32    0.609
  Moissidis             13      36       12       62     75     20    0.712
  Kabesch               34      33        6      471    263     39    0.770
  Battle                95     126       42       58     85     30    0.905
  Kang                  236    128       10      156     79     6     0.276
  Kim                   455    236       25      155     80     6     0.246
  Black                 158     98        7      1609   673     80    0.353
  Daley                 425    195       22      490    234     27    0.886
  H Li                  136     47        9      141     45     6     0.312
  Wang                  321    113       12      357    136     18    0.265
  Bottema               67      43        5       65     23     4     0.301
  Dmitrieva-Zdorova     149    116       18      117     94     16    0.623
  Undarmaa 1            190    117       18      227     98     11    0.915
  Undarmaa 2            230    121       16      459    196     21    0.989
  Yang XX               144     43        6      148     50     6     0.484
  Baye 1                243    148       22      187     98     13    0.972
  Baye 2                115    151       49       18     25     8     0.889
  Munoz                 45      34       11       58     46     7     0.594
  +2044A/G                                                           
  Hakonarson             3      25       66       3      27     64    0.941
  Howard                11      52       89       9      44     67    0.637
  Kauppi                17      82       64       19     51     62    0.119
  Leung                 29      74       54       7      26     21    0.812
  Xi 1                   6      24       15       3      20     23    0.624
  Xi 2                   8      25       10       2      13     16    0.765
  Donfack 1              7      41       79       5      73    127    0.141
  Donfack 2              6      67       132      4      53    126    0.564
  Zhao                  52      60       18       50     42     8     0.842
  Battle                 9      81       171      5      52    117    0.787
  Kang                  48     166       160      28    100    101    0.673
  Chan                  43     136       94       17     70     54    0.431
  Kim                   90     318       301      28    100     99    0.724
  Black                 11      98       166      76    657    1729   0.161
  Daley                 22     196       426      21    209    520    0.999
  Jiang                  2      2        20       1      5      18    0.422
  Llanes                 2      38       68       4      54     87    0.194
  Wang                  49     194       203      59    234    212    0.646
  Feng                  10      19       17       3      10     30    0.128
  Bottema                6      51       57       3      24     62    0.721
  Dmitrieva-Zdorova     23     116       144      17     85    125    0.630
  Palikhe               56     200       207      50    174    206    0.158
  Undarmaa 1            36     144       145      34    149    156    0.856
  Undarmaa 2            39     162       166      65    289    322    0.989
  Wu XH                 36     111       105      18     84    125    0.465
  Yang LF               47      60       71       19     66     73    0.497
  DeWan                  5      34       65       23    171    309    0.915
  Baye 1                26     157       230      14    101    183    0.989
  Baye 2                 8      87       220      1      14     36    0.787
  Noguchi               113    438       387     232    1033   1111   0.718
  Munoz                 21      52       17       23     65     23    0.071

CC or AA;

CT or AG;

TT or GG.

HWE, Hardy-Weinberg equilibrium.

Quantitative Data Synthesis {#s3b}
---------------------------

### The *IL-13* −1112C/T polymorphism {#s3b1}

Twenty-two studies determined the association between −1112C/T polymorphism and asthma. The sample sizes for case and control groups were 5834 and 8110, respectively. The estimated OR1, OR2 and OR3 were 1.32 (*P* = 0.002), 1.17 (*P* = 0.002), and 1.12 (*P* = 0.21) ([**Table 3**](#pone-0056065-t003){ref-type="table"}). These estimates suggested a dominant genetic model, therefore TT and TC were combined and compared with CC. The pooled OR was 1.20 (95% CI 1.08--1.34, *P* = 0.0009) ([**Figure 2**](#pone-0056065-g002){ref-type="fig"}). There was moderate heterogeneity (*I^2^* = 42%, *P = *0.02). In the stratified analysis by ethnicity, a statistically significant association was found for studies with Caucasians (OR = 1.30, 95% CI 1.09--1.55, *P = *0.003). However, no significant association was observed in Asians and African Americans ([**Table 3**](#pone-0056065-t003){ref-type="table"}). In the subgroup analysis by atopic status, the *IL-13* −1112C/T polymorphism was significantly associated with risk of atopic asthma (OR = 1.25, 95% CI 1.07--1.45, *P = *0.004) but not with non-atopic asthma risk (OR = 1.28, 95% CI 0.97--1.68, *P = *0.08). Of note, heterogeneity was significantly decreased in atopic asthma subgroup and non-atopic asthma subgroup (*I^2^* = 22%, *P = *0.24, and *I^2^* = 0%, *P = *0.86, respectively).

![Meta-analysis for the association between asthma risk and the *IL-13* −1112C/T polymorphism.](pone.0056065.g002){#pone-0056065-g002}

10.1371/journal.pone.0056065.t003

###### Determination of the genetic effects of *IL-13* polymorphisms on asthma and subgroup analyses.
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  Polymorphisms      Study      Sample size   No. of studies   Test of association         Model         Heterogeneity                              
  --------------- ------------ ------------- ---------------- --------------------- ------------------- --------------- -------- --- ------- ------ ------
  −1112C/T                                                                                                                                          
  TT vs. CC         Overall        3776            5571                22            1.32 (1.11--1.58)       3.17        0.002    R   27.19   0.16   23.0
  TC vs. CC         Overall        5461            7742                22            1.17 (1.06--1.30)       3.06        0.002    R   30.35   0.09   31.0
  TT vs. TC         Overall        2431            2907                22            1.12 (0.94--1.34)       1.26         0.21    R   14.98   0.82   0.0
  TT+TC vs. CC      Overall        5834            8110                22            1.20 (1.08--1.34)       3.32        0.0009   R   35.99   0.02   42.0
  TT+TC vs. CC       Asian         2713            2501                 8            1.13 (0.97--1.32)       1.16         0.11    R   10.55   0.16   34.0
  TT+TC vs. CC     Caucasian       2277            5045                10            1.30 (1.09--1.55)       2.95        0.003    R   17.87   0.04   50.0
  TT+TC vs. CC      African         844            564                  4            1.16 (0.80--1.67)       0.77         0.44    R   6.21    0.10   52.0
                    American                                                                                                                        
  TT+TC vs. CC       Atopic        2198            2390                10            1.25 (1.07--1.45)       2.90        0.004    R   11.60   0.24   22.0
  TT+TC vs. CC     Non-atopic       297            952                  5            1.28 (0.97--1.68)       1.73         0.08    R   1.29    0.86   0.0
  +2044A/G                                                                                                                                          
  AA vs. GG         Overall        4808            7055                31            1.28 (1.13--1.46)       3.81        0.0001   R   32.41   0.35   7.0
  AG vs. GG         Overall        7277           10304                31            1.15 (1.06--1.25)       3.38        0.0007   R   37.69   0.16   20.0
  AA vs. AG         Overall        4151            4935                31            1.11 (0.99--1.25)       1.78         0.08    R   20.39   0.91   0.0
  AA+AG vs. GG      Overall        8118           11147                31            1.18 (1.08--1.28)       3.78        0.0002   R   44.30   0.04   32.0
  AA+AG vs. GG       Asian         4770            5603                16            1.19 (1.04--1.36)       2.49         0.01    R   29.20   0.02   49.0
  AA+AG vs. GG     Caucasian       2463            4633                11            1.22 (1.06--1.40)       2.82        0.005    R   13.25   0.21   25.0
  AA+AG vs. GG      African         781            408                  3            1.13 (0.86--1.47)       0.88         0.38    R   0.25    0.88   0.0
                    American                                                                                                                        
  AA+AG vs. GG       Atopic        2486            2827                12            1.12 (1.00--1.26)       1.92         0.05    R   10.60   0.48   0.0
  AA+AG vs. GG     Non-atopic       259            789                  5            0.87 (0.60--1.27)       0.72         0.47    R   5.42    0.25   26.0

vs., versus; R, random-effects model.

We conducted one-way sensitivity analysis to evaluate the stability of the meta-analysis. As shown in [**Figure 3**](#pone-0056065-g003){ref-type="fig"}, the statistical significance of the results was not altered when any single study was omitted. Cumulative meta-analyses of *IL-13* −1112C/T polymorphism association were also conducted. The inclination toward significant association with asthma risk was found ([**Figure 4**](#pone-0056065-g004){ref-type="fig"}). The funnel plot was seemed symmetrical ([**Figure 5**](#pone-0056065-g005){ref-type="fig"}). However, Egger's test indicated significant publication bias (*P = *0.021).

![One-way sensitivity analysis for the *IL-13* −1112C/T polymorphism with asthma risk.](pone.0056065.g003){#pone-0056065-g003}

![Cumulative meta-analysis of associations between the *IL-13* −1112C/T polymorphism and asthma risk.](pone.0056065.g004){#pone-0056065-g004}

![Funnel plot for asthma risk and the *IL-13* −1112C/T polymorphism.](pone.0056065.g005){#pone-0056065-g005}

### The *IL-13*+2044A/G polymorphism {#s3b2}

Thirty-one case-control studies identified an association between *IL-13*+2044A/G polymorphism and asthma risk. A total of 8118 cases and 11147 controls were included in this meta-analysis. The estimated OR1, OR2 and OR3 were 1.28 (*P* = 0.0001), 1.15 (*P* = 0.0007), and 1.11 (*P* = 0.08), respectively ([**Table 3**](#pone-0056065-t003){ref-type="table"}). Thus, these estimates suggested a dominant genetic model, therefore AA and AG were combined and compared with GG. The pooled OR was 1.18 (95% CI 1.08--1.28, *P* = 0.0002) ([**Figure 6**](#pone-0056065-g006){ref-type="fig"}). Moderate heterogeneity (*I^2^* = 32%, *P = *0.04) was found. Subgroup analysis was performed by ethnicity. Statistically significant findings were witnessed in Asians (OR = 1.19, 95% CI 1.04--1.36, *P = *0.01) and Caucasians (OR = 1.22, 95% CI 1.06--1.40, *P = *0.005) but not in African Americans. In terms of atopic status, borderline yet significant increased asthma risk was found among atopic asthma patients (OR = 1.12, 95% CI 1.00--1.26, *P = *0.05), but no statistically significant finding was found among non-atopic asthma patients (OR = 0.87, 95% CI 0.60--1.27, *P = *0.47). Again, significant decreased heterogeneity was found in atopic asthma subgroup and non-atopic asthma subgroup (*I^2^* = 0%, *P = *0.48, and *I^2^* = 26%, *P = *0.25, respectively).

![Meta-analysis for the association between asthma risk and the *IL-13*+2044A/G polymorphism.](pone.0056065.g006){#pone-0056065-g006}

In the one-way sensitivity analysis, there was little modification of the estimates after exclusion of individual study ([**Figure 7**](#pone-0056065-g007){ref-type="fig"}). Cumulative meta-analysis showed that the evidence was consistent over time ([**Figure 8**](#pone-0056065-g008){ref-type="fig"}). The shape of the funnel plots seemed symmetrical in the dominant genetic model ([**Figure 9**](#pone-0056065-g009){ref-type="fig"}). Egger's test was used to provide statistical evidence of funnel plot symmetry. The result did not show any evidence of publication bias (*P = *0.684).

![One-way sensitivity analysis for the *IL-13*+2044A/G polymorphism with asthma risk.](pone.0056065.g007){#pone-0056065-g007}

![Cumulative meta-analysis of associations between the *IL-13*+2044A/G polymorphism and asthma risk.](pone.0056065.g008){#pone-0056065-g008}

![Funnel plot for asthma risk and the *IL-13*+2044A/G polymorphism.](pone.0056065.g009){#pone-0056065-g009}

Discussion {#s4}
==========

Hallmarks of asthma include airway inflammation predominated by eosinophils, mucus hyperproduction, and airway hyperresponsiveness (AHR) [@pone.0056065-Murphy1]. A considerable weight of evidence supporting a role for IL-13 in asthma was derived from animal models. For instance, previous studies showed that acute administration of IL-13 itself was sufficient to recapitulate eosinophilic inflammation in nonimmunized mice or recombination-activating gene-deficient mice [@pone.0056065-WillsKarp1], [@pone.0056065-Grnig1]. In addition, blockade of IL-13 alone in vivo through *IL-13* gene targeting in mice prevented and reversed established mucus cell changes, suggesting a key role of IL-13 in mucus hyperproduction [@pone.0056065-Blease1], [@pone.0056065-McKenzie1] Furthermore, AHR can be induced by IL-13 overexpression and blockade of IL-13 by the soluble receptor-Fc fusion protein abrogated allergen-induced AHR [@pone.0056065-Venkayya1]. Taken together, these results suggested that IL-13 was a critical cytokine in the development of asthma. *IL-13* was one of the most studied of the candidate genes for asthma. *IL-13* −1112C/T polymorphism led to increased *IL-13* transcription in polarized TH2 cells and enhanced IL-13 secretion by mitogen-stimulated mononuclear cells [@pone.0056065-Cameron1]. Moreover, Arima et al. [@pone.0056065-Arima1] indicated that the *IL-13*+2044A/G polymorphism may be a functional variant. Studies demonstrated that the AA genotype resulted in decreased affinity of IL-13 for IL-13Rα2 and increased expression of IL-13 [@pone.0056065-Arima1]. Thus, it is biologically plausible that these two polymorphisms could influence the susceptibility to asthma.

In the present meta-analysis, we explored the association between the *IL-13* −1112C/T and +2044A/G polymorphisms and asthma risk, including 34 eligible case-control studies. For *IL-13* −1112C/T polymorphism, 5834 cases and 8110 controls were included. We found that individuals with the −1112T allele (TT or TC) showed an increased risk of asthma in the overall population. The results from meta-analysis showed that carriers of the TT or TC genotype had 20% increased asthma risk compared to those individuals with the CC carriers. In the stratified analysis by ethnicity, the significant association was observed in Caucasians, but not in Asians and African Americans. It is possible that different genetic backgrounds may account for these differences. However, there were only four studies using African Americans. Thus, the positive association between African Americans and asthma could not be ruled out because studies with small sample size may have insufficient statistical power to detect a slight effect. In addition, significant heterogeneity (*I^2^* = 52%, *P = *0.10) may also distort the result. In the subgroup analysis by atopic status, we found *IL-13* −1112C/T polymorphism exhibited increased atopic asthma risk. For *IL-13*+2044A/G polymorphism, 8118 cases and 11147 controls were included. There was a significant association between this polymorphism and asthma risk. When subgroup analysis was performed according to ethnicity, significant associations were showed in Asians and Caucasians, but not in African Americans. Only three studies were performed with African Americans, thus the positive association still can not be excluded. The subgroup analysis based on atopic status found that *IL-13*+2044A/G polymorphism was marginally associated with allergic asthma risk. Taken together, these results suggested that *IL-13* polymorphisms may play a role in the etiology of allergic asthma.

A recent meta-analysis performed by Yang et al. [@pone.0056065-Yang3] found +2044A/G polymorphism was associated asthma risk in Asians but not in Caucasians. Another meta-analysis conducted by Cui et al. [@pone.0056065-Cui1] showed this polymorphism was more pronounced among Caucasians but not among Asians. Results from our study were inconsistent with these meta-analyses. We found significant associations in both Asians and Caucasians. There are several potential explanations for the different results. First, different inclusion and exclusion criteria were used in these two meta-analyses [@pone.0056065-Yang3], [@pone.0056065-Cui1]. For example, Cui et al. [@pone.0056065-Cui1] only included English papers. However, Yang et al. [@pone.0056065-Yang3] included articles published in English and Chinese. Thus, although these two meta-analyses were published in the same year, it was possible that different results may be observed. Second, different numbers of subjects were included in the two meta-analyses [@pone.0056065-Yang3], [@pone.0056065-Cui1]. For +2044A/G polymorphism, Cui et al. [@pone.0056065-Cui1] included 8439 subjects in their study, while Yang et al. [@pone.0056065-Yang3] only included 5695 subjects in their meta-analysis. Third, we noted that three studies (n = 806) performed using Caucasians and nine studies (n = 4241) performed using Asians were included in Yang's study [@pone.0056065-Yang3]. Moreover, six studies (n = 4202) conducted in Caucasians and five studies (n = 3673) conducted in Asians were included in Cui's study [@pone.0056065-Cui1]. Therefore, different statistical power might be another reason for the discrepant results. For +2044A/G polymorphism, our meta-analysis included eleven case-control studies (n = 7096) in Caucasians and sixteen case-control studies (n = 10373) in Asians, thus our study was more conclusive and more powerful. Additionally, our study had some advantages. First, we attempted to find as many publications as we could by means of various searching approaches. Second, it is the first time studying the atopic specificity and *IL-13* polymorphisms interactions. Third, the methodological issues for meta-analysis, such as, one-way sensitivity analysis and cumulative meta-analysis were well investigated.

Results from one-way sensitivity analysis and cumulative meta-analysis suggested high stability and reliability of our results. Besides, we had to mention the importance of heterogeneity and publication bias, which might influence the results of meta-analysis. In our study, moderate heterogeneity was observed for the *IL-13* −1112C/T and +2044A/G polymorphisms. We used subgroup analysis to explore the sources of heterogeneity. After subgroup analysis by atopic status, the heterogeneity was effectively decreased and disappeared. Therefore, the main source of heterogeneity was from atopic status. Moreover, funnel plots and Egger's tests were used to find potential publication bias. The results indicated that there was significant publication bias for *IL-13* −1112C/T polymorphism. Thus, our results should be interpreted with caution and more studies are still needed to evaluate the effect of *IL-13* −1112C/T polymorphism on asthma risk.

Several limitations need to be addressed. First, the numbers of published studies were not sufficient for a comprehensive analysis, particularly for African Americans. Second, our results were based on unadjusted estimates. Lacking of the original data of the eligible studies limited the evaluation of the effects of the gene-gene and gene-environment interactions in asthma. Third, Vercelli [@pone.0056065-Vercelli1] suggested that *IL-13* −1112C/T and +2044A/G were in high linkage disequilibrium. However, we did not carry out haplotype analysis due to limited data.

In conclusion, this meta-analysis suggested that *IL-13* −1112C/T and +2044A/G polymorphisms may be associated with the risk of asthma. Well-designed studies with larger sample size and more ethnic groups should be considered to further confirm these associations, especially in African Americans.
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